Compare Meta Platforms Inc (META) vs Nuvalent Inc (NUVL) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Meta Platforms Inc vs Nuvalent Inc — how do they compare? Meta Platforms Inc trades at $647.19 (market cap $1.64T), while Nuvalent Inc trades at $123.96 (market cap $9.81B). The key difference: Meta Platforms Inc is far larger — about 167.2× Nuvalent Inc's market cap, and Meta Platforms Inc pays a 0.33% dividend while Nuvalent Inc pays none. Which is the better fit depends on your goals.
| META | NUVL | |
|---|---|---|
Market Cap | $1.64T | $9.81B |
Volume | 24,093,972 | — |
Sector | Media | Technology |
52-Week High | $790.00 | $123.96 |
52-Week Low | $525.72 | $72.16 |
Enterprise Value | $1.65T | $8.52B |
Dividend Yield | 0.33% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Meta Platforms (META) trades at $646.96, up 0.15% with a bullish technical signal supported by moving averages. The company demonstrates strong fundamentals with $201B revenue in 2025, 32.84% net margin, and consistent earnings beats. Recent AI developments including Muse Spark launch and a $21B CoreWeave deal highlight growth initiatives. Technical indicators show support at $631 and resistance at $657, with RSI in neutral territory suggesting balanced momentum.
Outlook remains positive with 79% analyst buy ratings and $817 consensus target offering 26% upside. Key opportunities include AI monetization and revenue growth to $215B in 2026. Risks involve ongoing youth addiction lawsuits, regulatory scrutiny, and high capital expenditures. Institutional ownership trends show continued confidence with recent stake increases by American National Bank.
Nuvalent (NUVL) trades at $123.96, unchanged on the day, with a bullish technical signal from moving averages but overbought oscillators. The company reported a net loss of $425.38 million for 2025 and negative cash flow from operations. Recent news is dominated by GSK's proposed acquisition of Nuvalent for $124 per share, announced in June 2026, which is under investigation by multiple law firms for fairness to shareholders.
The investment outlook is heavily influenced by the pending acquisition. While analyst consensus shows no sell ratings, the stock price is near the offer price, limiting upside. Key risks include the deal's completion and the company's ongoing losses. The primary opportunity is the acquisition premium, but fundamental challenges persist absent the deal.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Meta Platforms Inc
Meta Platforms Inc., doing business as Meta and previously known as Facebook Inc. It's a company that acts as a parent platform for Facebook, Messenger, Instagram, Whatsapp, Oculus and other subsidiaries. Among these platforms, Facebook is the number one social media platform in terms of the number of active users.
Read more on META →About Nuvalent Inc
Nuvalent, Inc. is a clinical-stage oncology company focused on creating precisely targeted therapies for patients with cancers driven by specific gene mutations. The company leverages a deep understanding of structural biology and medicinal chemistry to design novel small-molecule kinase inhibitors to overcome resistance mechanisms in advanced solid tumors. Nuvalent is committed to developing its pipeline of candidates to address high unmet needs in the treatment of various cancers.
Read more on NUVL →
